AFINITOR vs EVEROLIMUS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 7, 2026·How we rate

Attribute	AFINITOR	EVEROLIMUS
Rating	70/100	72/100
Pharmacy pays	~$219.28 /30	~$219.28 /30
Type	RX	RX
Active ingredient	EVEROLIMUS	EVEROLIMUS
Manufacturer	Novartis	Biocon Pharma
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Half-life	about 30 hours (mean terminal elimination half-life)	about 30 hours (mean terminal elimination half-life)

afinitor everolimus

Rating

70/100

72/100

Pharmacy pays

~$219.28 /30

Type

Active ingredient

EVEROLIMUS

Manufacturer

Novartis

Biocon Pharma

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Half-life

about 30 hours (mean terminal elimination half-life)

Frequently asked questions

Which is better-rated, Afinitor or Everolimus?

By our independent rating, Everolimus scores higher — 3.6 vs 3.5 out of 5 for Afinitor. Ratings are based on FDA regulatory (recall-safety) data.

Which is cheaper, Afinitor or Everolimus?

Pharmacies pay about the same to acquire either one — roughly $219.28 for a 30-count supply, per the CMS NADAC survey. That is not what you will be charged: your price is set by your insurer and the pharmacy, not by what the drug cost them.

What is the difference between Afinitor and Everolimus?

Both Afinitor and Everolimus share the active ingredient Everolimus.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.